Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azathioprine dosing in Crohn's disease
NCT00113503Phase 2Terminated
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Jul 2005
- Primary completion
- Dec 2007
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of azathioprine in Crohn's disease (2 arms), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Primary endpoint: Clinical Remission at 16 weeks. Started Jul 2005; status: terminated.
02
Drugs
azathioprine
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00113503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00113503.